Last reviewed · How we verify

3-[18F]Fluoro-para-hydroxyphenethylguanidine

University of Michigan Rogel Cancer Center · Phase 1 active Small molecule Quality 0/100

3-[18F]Fluoro-para-hydroxyphenethylguanidine is a Small molecule drug developed by University of Michigan Rogel Cancer Center. It is currently in Phase 1 development. Also known as: [18F]3F-PHPG.

At a glance

Generic name3-[18F]Fluoro-para-hydroxyphenethylguanidine
Also known as[18F]3F-PHPG
SponsorUniversity of Michigan Rogel Cancer Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 3-[18F]Fluoro-para-hydroxyphenethylguanidine

What is 3-[18F]Fluoro-para-hydroxyphenethylguanidine?

3-[18F]Fluoro-para-hydroxyphenethylguanidine is a Small molecule drug developed by University of Michigan Rogel Cancer Center.

Who makes 3-[18F]Fluoro-para-hydroxyphenethylguanidine?

3-[18F]Fluoro-para-hydroxyphenethylguanidine is developed by University of Michigan Rogel Cancer Center (see full University of Michigan Rogel Cancer Center pipeline at /company/university-of-michigan-rogel-cancer-center).

Is 3-[18F]Fluoro-para-hydroxyphenethylguanidine also known as anything else?

3-[18F]Fluoro-para-hydroxyphenethylguanidine is also known as [18F]3F-PHPG.

What development phase is 3-[18F]Fluoro-para-hydroxyphenethylguanidine in?

3-[18F]Fluoro-para-hydroxyphenethylguanidine is in Phase 1.

Related